Why the study?
Does pre-discharge bio-adrenomedullin assessment identify hospitalised heart failure patients at high risk of early hospital readmission?
Does pre-discharge bio-adrenomedullin assessment identify hospitalised heart failure patients at high risk of early hospital readmission?
Pre-discharge bio-ADM levels reflect residual congestion and can identify heart failure patients at increased risk of early hospital readmission.
Association with rehospitalisation should not alter HF discharge practices; leaves open whether bio-ADM refines readmission prediction.
In hospitalised HF patients, elevated pre-discharge bio-ADM levels were associated with higher discharge loop diuretic doses and reflected residual congestion. Patients with combined higher bio-ADM levels and higher loop diuretic use at discharge had an increased risk of rehospitalisation. Assessment of discharge bio-ADM levels may be a readily applicable marker to identify patients with residual congestion at higher risk of early hospital readmission.
No takes yet. Share an insight, caveat, or question.
Pandhi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: